Description

Bausch + Lomb Corporation: Will The Growing Market Share in Contact Lens Business Last? 

Bausch + Lomb’s Q1 2024 earnings indicated a solid start to the year with notable growth across all its business units. Revenue increased by 20% on a constant currency basis, driven by outperformance from each of the company’s business units. The company’s growth was broad[1]based and did not depend on a specific business or region. Contact lenses were up 73%, while consumer products increased by 15%. The Surgical segment also saw an 8% growth. Their pharmaceuticals segment, excluding Xiidra, experienced an 18% organic revenue growth.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!